ArticleThe World Allergy Organization journal2025
Identification of the primary sensitizing mite (dominant mite) in patients with allergic respiratory disease sensitized to
Article in The World Allergy Organization journal, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Real-World Effectiveness and Safety of Allergen Immunotherapy with a Combination of Glutaraldehyde-Polymerized Allergen Extracts ofInternational journal of molecular sciences · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: To identify the dominant mite in patients with allergic respiratory disease (ARD) and double sensitization to Methods: Cross-sectional study including patients with Dpt and Ld sensitization (skin prick test [SPT] and specific IgE [sIgE]), with ARD. We measured sIgE to Dpt and Ld major allergens and performed CAP Inhibition experiments. The dominant mite was determined considering the Dpt/Ld ratio (≥5 Dpt and ≤0.2 Ld dominance) and CAP inhibition results (heterologous inhibition ≥50% indicates dominance). Results: We included 67 patients (62.7% men), with a mean (range) age of 35.8 (7-81) years. We found significant correlations between sIgE to Dpt whole extract (Dpt-sIgE) and sIgE to Der p 1, Der p 2, and Der p 23 ( Conclusions: In patients with ARD sensitized to Dpt and Ld, the sIgE Dpt/Ld ratio and, in specific situations, the Der p 1+Der p 23/Ld ratio, allow identification of the dominant mite in a high percentage of cases.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.